Results 181 to 190 of about 162,796 (303)

Hydroxamic Acids as HDAC Inhibitor Drug Leads for Malaria

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT Malaria is a global health threat, with an estimated 282 million cases and 610,000 malaria‐associated deaths reported in 2024. Most mortality is due to infection by Plasmodium falciparum parasites, with the highest burden occurring in Sub‐Saharan Africa.
Wisam A. Dawood   +7 more
wiley   +1 more source

Effects of D-Chiral Inositol on Amino Acid Metabolism in a PCOS Rat Model. [PDF]

open access: yesInt J Endocrinol
Zhao T   +8 more
europepmc   +1 more source

Improving Fetal Single‐Voxel Magnetic Resonance Spectroscopy With Spectral Registration

open access: yesMagnetic Resonance in Medicine, EarlyView.
ABSTRACT Purpose To evaluate whether spectral registration improves spectral quality and quantification reliability in in vivo single‐voxel fetal brain MRS: Methods Fourteen fetal PRESS datasets were acquired at 3 T at TE = 35 ms and TE = 135 ms. Raw data were processed with eddy‐current phase correction, coil combination, spectral registration, and ...
Andres Saucedo   +2 more
wiley   +1 more source

Imaging patterns and genetic associations of brain atrophy across distinct symptom stages in Parkinson's disease

open access: yesNeuroprotection, EarlyView.
Early disease stages showed limited cortical atrophy and enrichment of synaptic and calcium signaling pathways, whereas advanced stages demonstrated widespread cortical degeneration associated with immune activation and extracellular matrix remodeling.
Yi Ji   +6 more
wiley   +1 more source

Current status and future perspectives of platelet function‐guided precision antiplatelet therapy for patients with cerebral infarction

open access: yesNeuroprotection, EarlyView.
Antiplatelet agents target the cyclooxygenase‐1 (COX‐1)/thromboxane A2 (TXA2) and adenosine diphosphate (ADP)‐P2Y12 (cytochrome P450 2C19 [CYP2C19]‐metabolized) platelet activation pathways, resulting in either drug resistance or over‐inhibition. The individualized therapeutic window balances ischemic risk (triggered by high on‐treatment platelet ...
Guoliang Zhu   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy